comparemela.com

Latest Breaking News On - Orphazymeas stock exchange - Page 1 : comparemela.com

Change in management | MarketScreener

The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt. | May 30, 2023

United statesAnders fink vadsholtFink vadsholtZevra therapeuticsPreviously kempharmMichael hoveOrphazymeas stock exchangePress releaseHe orpha dk0060910917

Resolutions passed at the Annual General Meeting

Company announcement . | May 17, 2023

Jakob bendtsenBo jesper hansenJohn sommer schmidtAnders fink vadsholtGodkendt revisionspartnerselskabCompany registration noAudit committeeAnnual general meetingExecutive managementJesper hansenJakob haveMichael hoveOrphazymeas stock exchangePress releaseOmpany orpha dk0060910917

Major shareholder announcement | MarketScreener

Company announcement Orphazyme A/SNo. 09/2023 Ole Maaløes Vej 3DK-2200 Copenhagen N . | May 17, 2023

Company registration noDanish capital markets actOrphazymeas stock exchangePress releaseN orpha dk0060910917

Restructuring proposal adopted by creditors

Orphazyme A/S in restructuring Company. | May 30, 2022

John sommer schmidtAnders vadsholtDrug administrationCompany registration noHigh courtDanish maritimeCommercial high courtDanish insolvencyKempharm denmarkSubsequently orphazymeChief executive officerChief financial officerSommer schmidtRestructuring administratorNasdaq copenhagenOrphan drug designation

Correction: Proposal for a statutory restructuring plan

Orphazyme A/S in restructuringCompany announcementNo. 17/2022Inside information www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, April 4, 2022. | April 4, 2022

John sommer schmidtAnders vadsholtDrug administrationCompany registration noGlobenewswire incOrpha co orphazymeChief executive officerChief financial officerSommer schmidtRestructuring administratorNasdaq copenhagenOrphan drug designationFast track designationBreakthrough therapy designationRare pediatric disease designationComplete response letter

vimarsana © 2020. All Rights Reserved.